Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme | Zendy

Matthew J. McGirt | Zendy; Khoi D. Than | Zendy; Jon Weingart | Zendy; Kaisorn L. Chaichana | Zendy; Frank J. Attenello | Zendy; Alessandro Olivi | Zendy; John Laterra | Zendy; Lawrence Kleinberg | Zendy; Stuart A. Grossman | Zendy; Henry Brem | Zendy; Alfredo QuiñonesHinojosa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

Author(s) -

Matthew J. McGirt,

Khoi D. Than,

Jon Weingart,

Kaisorn L. Chaichana,

Frank J. Attenello,

Alessandro Olivi,

John Laterra,

Lawrence Kleinberg,

Stuart A. Grossman,

Henry Brem,

Alfredo QuiñonesHinojosa

Publication year - 2008

Publication title -

journal of neurosurgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.564

H-Index - 210

eISSN - 1933-0693

pISSN - 0022-3085

DOI - 10.3171/2008.5.17557

Subject(s) - medicine , concomitant , carmustine , temozolomide , surgery , radiation therapy , chemotherapy , cyclophosphamide

Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM). It remains unstudied whether combining Gliadel and TMZ therapy is safe or further improves survival in patients with newly diagnosed GBM. The authors reviewed their initial experience utilizing combined Gliadel, TMZ, and radiation therapy for the treatment of GBM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research